<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="8228">Pioglitazone</z:chebi>, a thiazolidinedione, has established efficacy in improving glycaemic control in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> also improves components of the mixed <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> profile common in these patients, as typified by raised levels of plasma <z:chebi fb="4" ids="17855">triglycerides</z:chebi>, low levels of <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> (<z:chebi fb="0" ids="47775">HDL-C</z:chebi>) and a raised proportion of <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> (<z:chebi fb="0" ids="47774">LDL-C</z:chebi>) occurring as the small dense subfraction </plain></SENT>
<SENT sid="2" pm="."><plain>In head-to-head trials, <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> has consistently shown superior benefits on <z:chebi fb="0" ids="47774">LDL-C</z:chebi> and <z:chebi fb="0" ids="47775">HDL-C</z:chebi> as well as <z:chebi fb="4" ids="17855">triglycerides</z:chebi> compared with <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> and sulphonylureas </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> used as monotherapy or combination therapy reduces levels of small dense LDL3 particles while raising levels of larger and less atherogenic <z:chebi fb="15" ids="39026">LDL</z:chebi> fractions </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> reduces cholesterol load and particle numbers of LDL3 </plain></SENT>
<SENT sid="5" pm="."><plain>Importantly, the differential effects of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> on <z:chebi fb="15" ids="39026">LDL</z:chebi> subfractions are complimentary and additive to those of <z:chebi fb="0" ids="9150">simvastatin</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> increases total <z:chebi fb="0" ids="47775">HDL-C</z:chebi> levels by 10-20%, mainly because of an increase in the larger HDL2 subfraction </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> also significantly reduces plasma <z:chebi fb="0" ids="17855">triglyceride</z:chebi> levels by 10-25% </plain></SENT>
<SENT sid="8" pm="."><plain>In recent studies, <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> significantly reduced carotid and <z:hpo ids='HP_0004929'>coronary atherosclerosis</z:hpo> compared with the sulphonylurea <z:chebi fb="0" ids="5383">glimepiride</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>The antidyslipidaemic effects of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi>--in particular, improvements in <z:chebi fb="0" ids="47775">HDL-C</z:chebi> and reduction of small dense LDL3--may have contributed to these effects </plain></SENT>
</text></document>